SEC Company Response from SciSparc Ltd. (SPRC) (CIK 0001611746) (SPRC) — Mar 20, 2017
SciSparc Ltd. (SPRC) (CIK 0001611746)
Date: March 20, 2017 · CIK: 0001611746 · Accession: 0001213900-17-002595
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214458
Letter
Therapix Biosciences Ltd.
5 Azrieli Center (Square Tower)
Tel-Aviv 6702501, Israel
March 20, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE: Therapix Biosciences Ltd. (CIK: 0001611746)
Registration Statement No. 333-214458 on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
Therapix Biosciences Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on March 21, 2017 at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
Very truly yours,
Therapix Biosciences Ltd.
Show Raw Text
CORRESP
1
filename1.htm
Therapix Biosciences Ltd.
5 Azrieli Center (Square Tower)
Tel-Aviv 6702501, Israel
March 20, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE:
Therapix Biosciences Ltd. (CIK: 0001611746)
Registration Statement No. 333-214458 on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
Therapix Biosciences
Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration
Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that
it may become effective on March 21, 2017 at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant understands
that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation
of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public
offering of the securities specified in the Registration Statement.
Very truly yours,
Therapix Biosciences Ltd.
By:
/s/ Dr. Elran Haber
Dr. Elran Haber, Chief Executive Officer